Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotheraphy
RA Reisfeld, BM Mueller, R Handgretinger… - Progress in Brain …, 1994 - Elsevier
Publisher Summary This chapter discusses the potential of genetically engineered anti-
ganglioside GD2 antibodies for cancer immunotherapy. These molecular constructs could
be produced by combining hybridoma methodology with recombinant DNA technology.
Although it seems that most of the human anti-mouse antibody (HAMA) problems occurring
with murine monoclonal antibodies (mAbs) have been solved by the development of
chimeric human/murine mAbs, a number of challenges have to be met before monoclonal …
ganglioside GD2 antibodies for cancer immunotherapy. These molecular constructs could
be produced by combining hybridoma methodology with recombinant DNA technology.
Although it seems that most of the human anti-mouse antibody (HAMA) problems occurring
with murine monoclonal antibodies (mAbs) have been solved by the development of
chimeric human/murine mAbs, a number of challenges have to be met before monoclonal …
